That does look like more of a concern. Eli Lilly have a market cap of nearly $600bn USD. I'm surprised this is the first I'm hearing of them. Their stock price is well and truly in the 'to infinity and beyond' category if you zoom out on google and look at the max time horizon.
Anyway, after listening to Mick's interview done overnight, it sounds like all weight loss drugs help with sleep apnea but the reduction in sleep apnea does not fall below the clinical threshold.
I am trying to find out more about Tirzepatide but so far it looks like it's a weight loss drug primarily. It just so happens that Eli lilly have decided to also do a trial on sleep apnea. Other weight loss drug manufacturers could have done the same trial but they didn't bother. Is that kind of how you view it?
Ann: ResMed Announces Results for the Fourth Quarter of FY2023, page-193
-
- There are more pages in this discussion • 179 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$36.90 |
Change
-0.700(1.86%) |
Mkt cap ! $23.45B | |||
| Open | High | Low | Value | Volume |
| $37.36 | $37.42 | $36.84 | $32.54M | 878.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 422 | $39.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.25 | 8966 | 1 |
View Market Depth
| Last trade - 15.59pm 13/09/2024 (20 minute delay) ? |
| RMD (ASX) Chart |